Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

s, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and plans regarding partnering and outlicensing activities and the participation at upcoming scientific conferences. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger- scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, the risks associated with further clinical trials, development and commercialization of product candidates, and the risks associated with recruiting and retention of individuals in key management functions. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Micromet, Inc.


'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... ... Since its inception in 2004 PhUSE has become the ... for European Statistical Programmers, has evolved in the past eleven years to a ... Managers and Biostatisticians all over the world, share, contribute and advance at various ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia Alliance, a ... in life science R&D, has attracted a number of new members from across ... pharmaceutical company joining as a Core member, and DNAnexus and Tessella as Participating ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Personalized Medicine, recently hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting ... with Proove Biosciences’ executive Research and Development team to discuss new clinical practice ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... molecular diagnostic tests are key drivers of the global molecular diagnostics market. BCC ... and the introduction of new companion diagnostic tests will increase demand for inexpensive ...
Breaking Biology Technology:PhUSE Delighted to Welcome Member Number 5.000 2Pistoia Alliance Continues to Attract New Members 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3
... computing that you should improve processes before you automate them. ... could just get its act together and tell us clearly ... only objective is to automate what youre already doing, it ... of technology value on the table and presumes the luxury ...
... Lucigen Corporation has been awarded the maximum ... under a special SBIR grant program for its enzyme ... new products and technologies with high potential value. , ... funds raised by Lucigen from outside investors. , ,The ...
... that it will repurchase up to 5% of its ... the open market or in private transactions in a ... ,"Third Wave's stock repurchase program underscores the confidence of ... and long-term outlook," said John Puisis, president and CEO ...
Cached Biology Technology:Innovate, Automate, or Improve? You Don't Have to Choose. 2Innovate, Automate, or Improve? You Don't Have to Choose. 3
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... competing for awards that recognize their research, according to ... Science Foundation and sponsored by the Association for Women ... teaching awards in proportion to the number of women ... Anne Lincoln at Southern Methodist University in Dallas. That,s ...
... by scientists from the Virginia Bioinformatics Institute (VBI) at ... distinct genetic changes differentiating cancer patients from healthy individuals ... The multidisciplinary team, which includes researchers from ... a design for a new DNA microarray that allows ...
... Starting in 2011, Chinese Science Bulletin , ... will be published as open access journals and added to ... Chinese Library of Science (CLoS), a collection comprising more than ... www.springerlink.com . Chinese Science Bulletin and ...
Cached Biology News:Gender gap: Selection bias snubs scholarly achievements of female scientists 2New technology pinpoints genetic differences between cancer and non-cancer patients 2Selected journals in Springer's Chinese Library of Science join SpringerOpen 2
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... High Performance, 5 ml. The same ... HiTrap Streptavidin columns for fast, reliable ... into Tricorn 5/50 GL, XK 16/20, ... purifications are required.Extremely useful for exploiting ...
... Immunogen: Synthetic peptide derived ... human SENP1. Specificity: Specific ... SENP1. Reactivity: Human (positive ... Hep2 cell lysates HL-60 cell ...
...
Biology Products: